Business Context and Reporting Period
This Form 6-K filing by Smith & Nephew plc is dated August 14, 2024. The document serves as a notification and public disclosure in accordance with the Market Abuse Regulation regarding transactions by Persons Discharging Managerial Responsibilities (PDMR) and persons closely associated with them. The filing details the vesting of share awards under the Global Share Plan 2020 and subsequent sales to cover tax liabilities.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. It exclusively reports on specific equity transactions involving company executives.
| Transaction Date | Instrument | Transaction Price (£) | Exchange |
|---|---|---|---|
| August 13, 2024 | Ordinary Shares (USD 0.20 each) | 11.403054 | London Stock Exchange (XLON) |
Material Changes and Transactions
The filing reports the following specific transactions involving PDMRs on August 13, 2024:
- Craig Gaffin (President, Orthopaedics):
- 2021 Awards: 595 shares vested (final tranche). 146 shares sold to cover tax; 449 retained.
- Alison Parkes (Chief Compliance Officer):
- 2021 Awards: 1,218 shares vested (final tranche). 447 shares sold to cover tax; 771 retained.
- Rohit Kashyap (President, Advanced Wound Management and Global Commercial Operations):
- 2023 Awards: 23,201 shares vested (first tranche). 5,670 shares sold to cover tax; 17,531 retained.
Guidance, Outlook, and Risks
The filing text does not provide management commentary, financial guidance, outlook, risk factors, or contingencies. The document is strictly a regulatory disclosure of insider trading activity related to compensation vesting.
Investor Verification Checklist
- Verify the total number of shares sold versus retained for each executive to assess net insider selling pressure.
- Confirm the vesting schedule details for the 2021 and 2023 Global Share Plan awards referenced in the filing.
- Check the prevailing market price of Smith & Nephew shares on August 13, 2024, to validate the transaction price of £11.403054.
- Review the company's most recent Form 20-F or quarterly report for broader financial performance metrics, as this filing contains none.